| Fragile X syndrome W Saldarriaga, F Tassone, LY González-Teshima, JV Forero-Forero, ... Colombia medica 45 (4), 190-198, 2014 | 209 | 2014 |
| Genetic cluster of fragile X syndrome in a Colombian district W Saldarriaga, JV Forero-Forero, LY González-Teshima, ... Journal of human genetics 63 (4), 509-516, 2018 | 40 | 2018 |
| Chimeric antigen receptor T cell therapy in oncology–Pipeline at a glance: Analysis of the ClinicalTrials. gov database E Moreno-Cortes, JV Forero-Forero, PA Lengerke-Diaz, JE Castro Critical reviews in oncology/hematology 159, 103239, 2021 | 27 | 2021 |
| AngiomiRs: potential biomarkers of pregnancy’s vascular pathologies LM Rodríguez Santa, LY González Teshima, JV Forero Forero, ... Journal of Pregnancy 2015, 2015 | 20 | 2015 |
| Síndrome de deleción 22q11: bases embriológicas y algoritmo diagnóstico J Ramírez-Cheyne, JV Forero-Forero, LY González-Teshima, A Madrid, ... Revista Colombiana de Cardiología 23 (5), 443-452, 2016 | 8 | 2016 |
| Mosaicism in Fragile X syndrome: A family case series W Saldarriaga, LY González-Teshima, JV Forero-Forero, HT Tang, ... Journal of Intellectual Disabilities 26 (3), 800-807, 2022 | 6 | 2022 |
| Predictors and management of relapse to Axicabtagene Ciloleucel in patients with aggressive B-cell lymphoma JV Forero-Forero, PA Lengerke-Diaz, E Moreno-Cortes, M Melody, ... Hematology/Oncology and Stem Cell Therapy, 2021 | 4 | 2021 |
| CT-335 in vitro cytotoxic rechallenge to model active CAR-T and NK cell cytotoxic activity, exhaustion, and persistence E Moreno, J Forero-Forero, JE Garcia-Robledo, N Booth, ... Clinical Lymphoma Myeloma and Leukemia 22, S443-S444, 2022 | 3 | 2022 |
| Preclinical NK Cell Platform for CAR Directed Therapies: Functional and Phenotypic Comparison Using a Rechallenge Cytotoxicity Assay JV Forero, EFM Cortes, JEG Robledo, N Booth, JE Castro Blood 138, 4805, 2021 | 3 | 2021 |
| Ibrutinib plus obinutuzumab as frontline therapy for chronic lymphocytic leukemia is associated with a lower rate of infusion-related reactions and with sustained remissions … JE Castro, PA Lengerke-Diaz, J Velez Lujan, MY Choi, EF Moreno-Cortes, ... Advances in Hematology 2022, 1-8, 2022 | 2 | 2022 |
| Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia PAL Diaz, MY Choi, EFM Cortes, JV Forero, J Velez-Lujan, ... Blood 136, 33-34, 2020 | 2 | 2020 |
| Emergence of micro-RNAs as potential biomarkers in different diseases JV Forero-Forero, LY González-Teshima, AM Cabal-Herrera, ... Iatreia 29 (3), 323-333, 2016 | 2* | 2016 |
| Síndrome de temblor y ataxia asociado a frágil X (FXTAS): revisión de la literatura W Saldarriaga Gil, JV Forero Forero, LY González Teshima, R Hagerman Acta Neurológica Colombiana 31 (3), 335-341, 2015 | 2 | 2015 |
| ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype E Moreno-Cortes, P Franco-Fuquen, JE Garcia-Robledo, J Forero, ... Frontiers in Oncology 13, 2023 | 1 | 2023 |
| Optimization of Third Generation Chimeric Antigen Receptor T Cells Targeting ROR1 for Hematological Malignancies EFM Cortes, JEG Robledo, N Booth, JV Forero, JE Castro Blood 138, 4804, 2021 | 1 | 2021 |
| Immune effector cell therapies in oncology: A systematic analysis and forecast from ClinicalTrials. gov. JV Forero-Forero, JE Garcia-Robledo, DA Castro-Martinez, EF Moreno, ... Journal of Clinical Oncology 39 (15_suppl), e14516-e14516, 2021 | 1 | 2021 |
| Aberrant Spliceosome Activity via Elevated Intron Retention and Upregulation and Phosphorylation of SF3B1 in Chronic Lymphocytic Leukemia MK Kashyap, H Karathia, D Kumar, RV Alvarez, JV Forero-Forero, ... Molecular Therapy-Nucleic Acids, 2024 | | 2024 |
| ICOS and OX40 Signaling Optimization Improves CAR-T Cell Persistence in Preclinical Models E Moreno, P Franco-Fuquen, JV Forero, JE Garcia Robledo, N Booth, ... Blood 140 (Supplement 1), 10251-10252, 2022 | | 2022 |
| Poster: CT-335 In Vitro Cytotoxic Rechallenge to Model Active CAR-T and NK Cell Cytotoxic Activity, Exhaustion, and Persistence E Moreno, J Forero-Forero, JE Garcia-Robledo, N Booth, ... Clinical Lymphoma, Myeloma and Leukemia 22, S188, 2022 | | 2022 |
| RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR-2: A NOVEL CELLULAR THERAPY TARGET FOR NEUROBLASTOMA N Booth, J Forero-Forero, E Moreno, J Garcia-Robledo, P Franco-Fuquen, ... PEDIATRIC BLOOD & CANCER 69, 2022 | | 2022 |
LAURA YURIKO GONZALEZ TESHIMAM.D., Universidad del ValleEmail confirmado em correounivalle.edu.co
